Breast Cancer
Conditions
Brief summary
RadioVal will develop and implement interoperable solutions for clinical deployment of the radiomics tools, including information, training, and communication packages for clinicians and patients, as well as standard operating procedures for the integration of radiomics in clinical oncology. With this study, we will clinically validate these solutions, by looking at their reliability for precise breast cancer diagnosis, treatment recommendation and prognosis estimate, treatment response, evaluation of residual disease and outcome prediction.
Interventions
OTHERThe development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer
Evaluate response to neoadjuvant treatment in advanced breast cancer
Sponsors
Karolinska Institutet
Medical University of Gdansk
Medical School University of Zagreb
Medical University of Vienna
Hacettepe University
Alexander Fleming Institute
Ain Shams University
Instituto de Investigacion Sanitaria La Fe
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 85 Years
Inclusion criteria
* Females ≥ 18 years up to 85 years old * Individuals referred to hospitals for diagnosis of breast cancer * Availability of radiological images: 2D mammography or 2D synthetic digital tomosynthesis, ultrasound, or magnetic resonance * Availability of pathological report (surgical specimen) * Availability of (Neoadjuvant) treatment allocation (scheme, duration, benefit) * Availability of treatment response
Exclusion criteria
* Patient with incomplete or low-quality data (radiological, pathological or clinical)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients non-respondents vs respondents in neoadjuvant breast cancer treatment (Estimate tumor aggressiveness) | Baseline and after neoadjuvant treatment (4-6 months) | Proportion of patients who have complete response evaluating the target lesion according to Miller/Payne Grading system \[Ogston et al., 2003\]: 1A. Evaluation of target Tumor: G5 as pathological complete response, no tumor left; G4:more than 90% loss of tumor cells; G3: between 30-90% reduction in tumor cells; G2: loss of tumor \<30%; G1: no reduction. 1B: Evaluating the lymph nodes: A: negative; B: lymph nodes with metastasis and without changes by chemotherapy; C: lymph nodes with metastasis with evidence of partial response, D: lymph nodes with changes attributed to response without residual infiltration. 1C: Using images to evaluated radiological response: Size and diameter in millimeters of the target lesion using RM and TC or PET/CT for extension analysis (lymph nodes and metastasis). |
Countries
Argentina, Austria, Croatia, Egypt, Poland, Spain, Sweden, Turkey (Türkiye)
Contacts
Primary ContactAna Penades-Blasco, M.Ec
Outcome results
None listed